Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ophthotech Corp.

Division of OphthoTech Corp.
www.ophthotech.com

Latest From Ophthotech Corp.

Appointments: Nordic Nanovector Loses CEO, Verona Pharma Loses CMO, Plus New CEOs At DalCor And PureTech Health

This week's announcements include two CEO resignations at Nordic Nanovector and Verona Pharma, new CEOs at DalCor Pharmaceuticals and PureTech Health, new CMOs at Medigene, Argenx, Pneuma Respiratory and ReNeuron, plus board appointments.

Appointments BioPharmaceutical

Pipeline Watch: Topline Readouts With Keytruda, Cosentyx And Zepsyre

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Pipeline Watch: Phase III Progress With Lefamulin, Dupilumab, Patisiran

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

Apellis Eyes Progress For Lead AMD Product

Apellis Pharmaceuticals' lead product APL-2 for geographic atrophy, a progressed form of age-related macular degeneration, has met its primary endpoint in a Phase II trial with the company planning to begin Phase III trials in 2018.

Clinical Trials Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • OphthoTech Corp.
  • Senior Management
  • Glenn P Sblendorio, Pres. & CEO
    David F Carroll, CFO
    Kourous A Rezaei, MD, SVP, CMO
  • Contact Info
  • Ophthotech Corp.
    Phone: (212) 845-8200
    One Penn Plaza, Ste. 3520
    New York, NY 10119
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register